Literature DB >> 19578455

The treatment of deep vein thrombosis in the pelvis and leg.

Viola Hach-Wunderle1, Markus Düx, Max Zegelman, Anja Hoffmann, Florian Präve, Wolfgang Hach.   

Abstract

INTRODUCTION: Deep vein thrombosis is associated with a risk of pulmonary embolism and post thrombotic syndrome (PTS).
METHODS: Selective literature review with special reference to the American College of Chest Physicians' current guidelines and the German S2 interdisciplinary guideline. RESULTS AND DISCUSSION: The most important therapeutic measure is prompt and adequate anticoagulation with heparin or fondaparinux. Thrombolysis or thrombectomy is only indicated in highly selected severe cases. The risk of PTS can be reduced by immediate ongoing treatment with compression stockings. Prevention of relapse is achieved using vitamin K antagonists with a target INR of 2.0 to 3.0. The duration of anticoagulation should be tailored to the localisation and etiology of the thrombosis, from at least three months to indefinite treatment. The ongoing risk of bleeding secondary to anticoagulation should be reevaluated at regular intervals as a cost-benefit analysis. New anticoagulants for acute and long term treatment will soon be available for clinical use.

Entities:  

Keywords:  anticoagulation; compression stockings; prevention of recurrence; thrombophilia; venous thrombosis

Year:  2008        PMID: 19578455      PMCID: PMC2701591          DOI: 10.3238/arztebl.2008.0025

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  30 in total

1.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

Review 2.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

3.  Heparin-induced thrombocytopenia associated with fondaparinux.

Authors:  Theodore E Warkentin; Brian T Maurer; Richard H Aster
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

4.  Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Martin H Prins; Enrico Bernardi; Antonio Marchiori; Paola Bagatella; Michela Frulla; Laura Mosena; Daniela Tormene; Andrea Piccioli; Paolo Simioni; Antonio Girolami
Journal:  Ann Intern Med       Date:  2002-12-17       Impact factor: 25.391

5.  A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.

Authors:  H Decousus; A Leizorovicz; F Parent; Y Page; B Tardy; P Girard; S Laporte; R Faivre; B Charbonnier; F G Barral; Y Huet; G Simonneau
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

6.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

7.  Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin.

Authors:  H Partsch; W Blättler
Journal:  J Vasc Surg       Date:  2000-11       Impact factor: 4.268

8.  Prevention and treatment of postphlebitic syndrome: results of a 3-part study.

Authors:  J S Ginsberg; J Hirsh; J Julian; M Vander LaandeVries; D Magier; B MacKinnon; M Gent
Journal:  Arch Intern Med       Date:  2001-09-24

Review 9.  The epidemiology of venous thromboembolism.

Authors:  Richard H White
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

10.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.